Altre lingue ASKA Pharmaceutical Holdings Co.,Ltd.

Azioni

4886

JP3119660003

Mercato chiuso - Japan Exchange Altri mercati azionari 08:00:00 12/07/2024			Variaz. 5gg	Var. 1 gen.
2.421 ^JPY	+0,88%		+0,08%	+35,71%

2023	ASKA Pharmaceutical Holdings Co.,Ltd. riporta i risultati degli utili per l'intero anno terminato il 31 marzo 2023	CI
2020	ASKA Pharmaceutical Co. annuncia il dividendo per l'anno conclusosi il 31 marzo 2020, pagabile il 26 giugno 2020; fornisce una guida ai dividendi per il secondo trimestre e per l'anno conclusosi il 31 marzo 2021; riporta i risultati degli utili consolidati per l'anno conclusosi il 31 marzo 2020; fornisce una guida agli utili consolidati per l'anno conclusosi il 31 marzo 2021	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area	31/05
ASKA Pharmaceutical : April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries	25/04
ASKA Pharmaceutical : March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication	26/03
ASKA Pharmaceutical : March 21 2024 Newsweek International Features ASKA Pharmaceutical	21/03
Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd.	21/12
ASKA Pharmaceutical : November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine	14/11
ASKA Pharmaceutical : September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo	22/09/23
ASKA Pharmaceutical : September 14 2023 Newsweek International Features ASKA Pharmaceutical	14/09/23
ASKA Pharmaceutical : July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)	20/07/23
ASKA Pharmaceutical : June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries	27/06/23
ASKA Pharmaceutical : June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA	22/06/23
ASKA Pharmaceutical : June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders	11/06/23
ASKA Pharmaceutical : June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS	11/06/23
ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma	09/06/23
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	11/05/23
ASKA Pharmaceutical : April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech	24/04/23
ASKA Pharmaceutical : April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities	21/04/23
ASKA Pharmaceutical : April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone	07/04/23
ASKA Pharmaceutical : April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment	07/04/23
ASKA Pharmaceutical : March 27 2023 Personnel Change of ASKA Pharmaceutical	27/03/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue ASKA Pharmaceutical Holdings Co.,Ltd.

Azioni

4886

JP3119660003

Altre lingue

Filtri